Tailoring combination oral contraceptives to the individual woman

Journal of Women's Health

Volumn 20, Issue 6, 2011, Pages 879-891

  Archer, David F ^a   Lasa, Ignacio Lete ^b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b HOSPITAL TXAGORRITXU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMADINONE ACETATE; CYPROTERONE ACETATE; DEMEGESTONE; DESOGESTREL; DIENOGEST; DROSPIRENONE; DYDROGESTERONE; ELCOMETRINE; ESTRADIOL VALERATE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ETHINYLESTRADIOL; ETONOGESTREL; GESTAGEN; GESTODENE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVONORGESTREL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYNESTRENOL; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; NOMEGESTROL ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; NORETYNODREL; NORGESTIMATE; PROGESTERONE; PROMEGESTONE; TRIMEGESTONE;

ACNE VULGARIS; BINDING AFFINITY; BLEEDING; CARBOHYDRATE METABOLISM; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HEMOSTASIS; HUMAN; LIPID METABOLISM; LONG TERM CARE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; ORAL CONTRACEPTION; PREMENSTRUAL DYSPHORIC DISORDER; PRIORITY JOURNAL; REVIEW; VENOUS THROMBOEMBOLISM;

CHEMISTRY, PHARMACEUTICAL; CONTRACEPTIVES, ORAL; ESTROGENS; FEMALE; HUMANS; META-ANALYSIS AS TOPIC; PROGESTINS; THROMBOEMBOLISM;

EID: 79959311110     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2010.2199     Document Type: Review

References (114)

1. Skouby SO. Contraceptive use and behavior in the 21st century: A comprehensive study across five european countries. Eur J Contraception Reprod Health Care 2004;9:57-68.
2. United Nations. World contraceptive use 2007. Available at www.un.org/esa/population/publications/contraceptive2007/contraceptive2007.htm Accessed July 16, 2009.
3. Guillebaud J. Youthquake: Population, fertility and environment in the 21st century, 2007. Available at www.optimumpopulation.org/Youthquake.pdf Accessed February 6, 2010.
4. Mishell DR Jr, Kletzky OA, Brenner PF, Roy S, Nicoloff J. The effect of contraceptive steroids on hypothalamic-pituitary function. Am J Obstet Gynecol 1977;128:60-74. (Pubitemid 8096219)
5. Benagiano G, Primiero FM, Farris M. Clinical profile of contraceptive progestins. Eur J Contraception Reprod Health Care 2004;9:182-193. (Pubitemid 39539580)
6. Gerstman BB, Gross TP, Kennedy DL, et al. Trends in the content and use of oral contraceptives in the United States, 1964-88. Am J Public Health 1991;81:90-96.
7. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2004;47:277-283. (Pubitemid 38523308)
8. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006;12:169-178. (Pubitemid 43231449)
9. Trussell J. Contraceptive failure in the United States. Contraception 2004;70:89-96. (Pubitemid 38993483)
10. Hannaford PC, Iversen L, Macfarlane TV, et al. Mortality among contraceptive pill users: Cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ 2010;340:c927.
11. Cibula D, Widschwendter M, Majek O, Dusek L. Tubal ligation and the risk of ovarian cancer: Review and metaanalysis. Hum Reprod 2011;17:55-67.
12. American College of Obstetricians and Gynecologists. Committee on Practice Bulletins. ACOG practice bulletin No. 110: Noncontraceptive uses of hormonal contraceptives. Obstet Gynecol 2010;115:206-218.
13. Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol 2004;190:S5-22.
14. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database of Systematic Reviews (online) 2009:CD004425.
15. Edgren RA, Stanczyk FZ. Nomenclature of the gonane progestins. Contraception 1999;60:313. (Pubitemid 30133218)
16. Sneader W. Steroid hormones. Drug prototypes and their exploitation, Chichester, England: John Wiley & Sons, 1996:303-360.
17. Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996:188-215. (Pubitemid 26039155)
18. Oelkers W, Berger V, Bolik A, et al. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: Effects on ovulation, electrolyte excretion, and the reninaldosterone system in normal women. J Clin Endocrinol Metab 1991;73:837-842. (Pubitemid 21921946)
19. Stanczyk FZ. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endocr Metab Disord 2002;3:211-224.
20. Schindler AE, Campagnoli C, Druckmann R, et al. Classi- fication and pharmacology of progestins. Maturitas 2003;46(Suppl 1):S7-S16.
21. McPhail MK. The assay of progestin. J Physiol (Lond) 1934;83:145-156.
22. Sitruk-Ware R. Pharmacology of different progestogens: The special case of drospirenone. Climacteric 2005;8 (Suppl 3):4-12. (Pubitemid 41608058)
23. Kuhl H. Pharmacokinetics of oestrogens and progestogens. Maturitas 1990;12:171-197. (Pubitemid 20279929)
24. Lello S. Nomegestrol acetate: Pharmacology, safety profile and therapeutic efficacy. Drugs 2010;70:541-559.
25. Ezan E, Benech H, Bucourt R, et al. Enzyme immunoassay for nomegestrol acetate in human plasma. J Steroid Biochem Mol Biol 1993;46:507-514. (Pubitemid 23312322)
26. Bouchard P. Chlormadinone acetate (cma) in oral contraception: A new opportunity. Eur J Contracept Reprod Health Care 2005;10 (Suppl 1):7-11. (Pubitemid 41790961)
27. Rudel HW, Maqueo M, Calderone J, Martinez-Manatou JM. Safety and effectiveness of a new low-dose oral contraceptive: A three-year study of 1,000 women. J Reprod Med 1978;21:79-88. (Pubitemid 9009757)
28. Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 lg (loestrin 24 fe). Contraception 2007;75:16-22. (Pubitemid 44854856)
29. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003;68:89-96. (Pubitemid 37101032)
30. Anderson FD, Gibbons W, Portman D. Long-term safety of an extended-cycle oral contraceptive (seasonale): A 2-year multicenter open-label extension trial. Am J Obstet Gynecol 2006;195:92-96. (Pubitemid 43927514)
31. Anderson FD, Gibbons W, Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception 2006;73:229-234. (Pubitemid 43202171)
32. Archer DF, Jensen JT, Johnson JV, et al. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: Phase 3 study results. Contraception 2006;74:439-445. (Pubitemid 46037535)
33. Kaunitz AM. Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (desogestrel/ethinyl estradiol) and ortho-novum 7/7/7 (norethindrone/ethinyl estradiol): A randomized clinical trial. Contraception 2000;61:295-302. (Pubitemid 30447450)
34. The Mircette Study Group. An open-label, multicenter, noncomparative safety and efficacy study of mircette, a low-dose estrogen-progestin oral contraceptive. The Mircette Study Group. Am J Obstet Gynecol 1998;179:S2-S8.
35. Runnebaum B, Grunwald K, Rabe T. The efficacy and tolerability of norgestimate/ethinyl estradiol (250 micrograms of norgestimate/35 micrograms of ethinyl estradiol): Results of an open, multicenter study of 59,701 women. Am J Obstet Gynecol 1992;166:1963-1968.
36. Affinito P, Monterubbianesi M, Primizia M, et al. Efficacy, cycle control and side effects of two monophasic combination oral contraceptives: Gestodene/ethinylestradiol and norgestimate/ethinylestradiol. Gynecol Endocrinol 1993;7:259-266. (Pubitemid 24042455)
37. LaGuardia KD, Shangold G, Fisher A, Friedman A, Kafrissen M. Efficacy, safety and cycle control of five oral contraceptive regimens containing norgestimate and ethinyl estradiol. Contraception 2003;67:431-437. (Pubitemid 36695107)
38. Skouby SO. Oral contraception with a triphasic combination of gestodene and ethinyl estradiol: Results of a multicenter clinical study. Int J Fertil 1987;32 (Suppl):45-48.
39. Grunenthal. Belara product monograph. Available at www.Belara.Com Accessed September 15, 2009.
40. Parsey KS, Pong A. An open-label, multicenter study to evaluate yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000;61:105-111. (Pubitemid 30236331)
41. Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contraception Reprod Health Care 2000;5:25-34. (Pubitemid 30321317)
42. Milsom I, Lete I, Bjertnaes A, et al. Effects on cycle control and bodyweight of the combined contraceptive ring, nuvaring, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3mg drospirenone. Hum Reprod 2006;21:2304-2311. (Pubitemid 44530604)
43. Bachmann G, Sulak PJ, Sampson-Landers C, Benda N, Marr J. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3mg drospirenone. Contraception 2004;70:191-198. (Pubitemid 39119980)
44. Bayer Healthcare. Qlaira. Summary of product characteristics. May 2009.
45. Wyeth. Lybrel. Prescribing information. Available at www.Lybrel.Com
46. Duramed. Seasonique. Prescribing information. Available at www.Seasonique.Com
47. Duramed. Seasonale. Prescribing information. Available at www.Seasonale.Com
48. McGuire JL, Phillips A, Hahn DW, et al. Pharmacologic and pharmacokinetic characteristics of norgestimate and its metabolites. Am J Obstet Gynecol 1990;163:2127-2131.
49. Hasenack HG, Bosch AM, Kaar K. Serum levels of 3-keto-desogestrel after oral administration of desogestrel and 3-keto-desogestrel. Contraception 1986;33:591-596. (Pubitemid 16014485)
50. Kaplan B. Desogestrel, norgestimate, and gestodene: The newer progestins. Ann Pharmacother 1995;29:736-742.
51. Foster RH, Wilde MI. Dienogest. Drugs 1998;56:825-833.
52. Basdevant A, Pelissier C, Conard J, et al. Effects of nomegestrol acetate (5 mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women. Contraception 1991;44:599-605.
53. Elger W, Beier S, Pollow K, et al. Conception and pharmacodynamic profile of drospirenone. Steroids 2003;68:891-905. (Pubitemid 37532413)
54. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995;80:1816-1821.
55. Bitzer J, Paoletti AM. Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone: Results of three multicentre trials. Clin Drug Invest 2009;29:73-78.
56. Bayer Pharmaceuticals. Yaz (drospirenone-ethinyl estradiol) package insert. Wayne, NJ: Bayer, 2007.
57. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: A prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998;179:577-582. (Pubitemid 28447229)
58. Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 microg versus> 20 microg estrogen combined oral contraceptives for contraception. Cochrane Database of Systematic Reviews (online) 2008:CD003989.
59. Maitra N, Kulier R, Bloemenkamp KW, Helmerhorst FM, Gulmezoglu AM. Progestogens in combined oral contraceptives for contraception. Cochrane Database of Systematic Reviews (online) 2004:CD004861.
60. Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001;344:1527-1535. (Pubitemid 32429213)
61. Heinemann LA, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007;75:328-336.
62. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: Final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007;75:344-354.
63. Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: National follow-up study. BMJ 2009;339:b2890.
64. World Health Organization. Collaborative study of cardiovascular disease and steroid hormone contraception. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. Lancet 1995;346:1575-1582.
65. Barbieri RL, Speroff L, Walker AM, McPherson K. Therapeutic controversy: The safety of third-generation oral contraceptives. J Clin Endocrinol Metab 1999;84:1822-1829. (Pubitemid 30646992)
66. Burkman RT. Venous thromboembolism and oral contraceptives: Current status and clinical implications. Treat Endocrinol 2002;1:143-147. (Pubitemid 36828421)
67. Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: A clinical review. Arch Intern Med 2004;164:1965-1976. (Pubitemid 39390552)
68. Bloemenkamp KW, Rosendaal FR, Buller HR, et al. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 1999;159:65-70. (Pubitemid 29044121)
69. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1593-1596. (Pubitemid 26001841)
70. Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: Cohort and case-control analysis. BMJ 2000;321:1190-1195.
71. Lewis MA, MacRae KD, Kuhl-Habichl D, et al. The differential risk of oral contraceptives: The impact of full exposure history. Hum Reprod 1999;14:1493-1499. (Pubitemid 29265441)
72. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: A five-year national case-control study. Contraception 2002;65:187-196. (Pubitemid 34258539)
73. Todd J, Lawrenson R, Farmer RD, Williams TJ, Leydon GM. Venous thromboembolic disease and combined oral contraceptives: A re-analysis of the Mediplus database. Hum Reprod 1999;14:1500-1505. (Pubitemid 29265442)
74. Parkin L, Skegg DC, Wilson M, Herbison GP, Paul C. Oral contraceptives and fatal pulmonary embolism. Lancet 2000;355:2133-2134. (Pubitemid 30364664)
75. Vasilakis-Scaramozza C, Jick H. Risk of venous thrombo-embolism with cyproterone or levonorgestrel contraceptives. Lancet 2001;358:1427-1429. (Pubitemid 33055749)
76. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: Results of the mega case-control study. BMJ 2009;339:b2921.
77. Schindler AE. Differential effects of progestins on hemostasis. Maturitas 2003;46 (Suppl 1):S31-37.
78. Wiegratz I, Lee JH, Kutschera E, Winkler UH, Kuhl H. Effect of four oral contraceptives on hemostatic parameters. Contraception 2004;70:97-106. (Pubitemid 38993484)
79. Zerr-Fouineau M, Chataigneau M, Blot C, Schini-Kerth VB. Progestins overcome inhibition of platelet aggregation by endothelial cells by down-regulating endothelial NO synthase via glucocorticoid receptors. FASEB J 2007;21:265-273. (Pubitemid 46052565)
80. Zerr-Fouineau M, Jourdain M, Boesch C, et al. Certain progestins prevent the enhancing effect of 17beta-estradiol on No-mediated inhibition of platelet aggregation by endothelial cells. Arterioscler Thromb Vasc Biol 2009;29:586-593.
81. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1995;273:199-208.
82. Sitruk-Ware R. Progestins and cardiovascular risk markers. Steroids 2000;65:651-658.
83. Kauppinen-Makelin R, Kuusi T, Ylikorkala O, Tikkanen MJ. Contraceptives containing desogestrel or levonorgestrel have different effects on serum lipoproteins and post-heparin plasma lipase activities. Clin Endocrinol (Oxf) 1992;36:203-209.
84. Yildizhan R, Yildizhan B, Adali E, et al. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure. Arch Gynecol Obstet 2009;280:255-261.
85. Machado RB, Fabrini P, Cruz AM, Maia E, da Cunha Bastos A. Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 microg) and gestodene (75 microg). Contraception 2004;70:365-3670.
86. Wiegratz I, Jung-Hoffmann C, Gross W, Kuhl H. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters. Contraception 1998;58:83-91. (Pubitemid 28449361)
87. Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: Effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database of Systematic Reviews (online) 2007:CD006133.
88. Visser J, Snel M, Van Vliet HA. Hormonal versus nonhormonal contraceptives in women with diabetes mellitus type 1 and 2. Cochrane Database of Systematic Reviews (online) 2006:CD003990.
89. Gorrill MJ, Marshall JR. Pharmacology of estrogens and estrogen-induced effects on nonreproductive organs and systems. J Reprod Med 1986;31:842-847. (Pubitemid 16030554)
90. Slater CC, Hodis HN, Mack WJ, et al. Markedly elevated levels of estrone sulfate after long-term oral, but not transdermal, administration of estradiol in postmenopausal women. Menopause 2001;8:200-203. (Pubitemid 32410992)
91. Stanczyk F. Estrogens used for replacement therapy in postmenopausal women. Gynecol Endocrinol 2001;15(Suppl 4):17-25. (Pubitemid 33731453)
92. Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1982;144:511-518. (Pubitemid 12002825)
93. Lindberg UB, Enk L, Crona N, Silfverstolpe G. A comparison of the effects of ethinyl estradiol and estradiol valerate on serum and lipoprotein lipids. Maturitas 1988;10:343-352. (Pubitemid 19011819)
94. Lindberg UB, Crona N, Stigendal L, Teger-Nilsson AC, Silfverstolpe G. A comparison between effects of estradiol valerate and low dose ethinyl estradiol on haemostasis parameters. Thromb Haemost 1989;61:65-69. (Pubitemid 19092670)
95. Nilsson S, Makela S, Treuter E, et al. Mechanisms of estrogen action. Physiol Rev 2001;81:1535-1565. (Pubitemid 32951806)
96. de Gooyer ME, Deckers GH, Schoonen WG, Verheul HA, Kloosterboer HJ. Receptor profiling and endocrine interactions of tibolone. Steroids 2003;68:21-30. (Pubitemid 35422732)
97. Kuhl H. Pharmacology of estrogens and progestogens: Influence of different routes of administration. Climacteric 2005;8 (Suppl 1):3-63. (Pubitemid 41232429)
98. Ansbacher R. The pharmacokinetics and efficacy of different estrogens are not equivalent. Am J Obstet Gynecol 2001;184:255-263. (Pubitemid 32208274)
99. Serup J, Bostofte E, Larsen S, Westergaard J, Lebech PE. Natural oestrogens for oral contraception. Lancet 1979;314:471-472. (Pubitemid 9250419)
100. Serup J, Bostofte E, Larsen S, Westergaard J. Effectivity and acceptability of oral contraceptives containing natural and artificial estrogens in combination with a gestagen. A controlled double-blind investigation. Acta Obstet Gynecol Scand 1981;60:203-206. (Pubitemid 11113403)
101. Endrikat J, Parke S, Trummer D, et al. Ovulation inhibition with four variations of a four-phasic estradiol valerate/ dienogest combined oral contraceptive: Results of two prospective, randomized, open-label studies. Contraception 2008;78:218-225.
102. Ahrendt HJ, Makalova D, Parke S, Mellinger U, Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: A seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception 2009;80:436-444.
103. Duijkers I, Klipping C, Grob P, Korver T. Endometrial and cervical mucus responses to a unique, monophasic combined oral contraceptive containing nomegestrol acetate/17 beta-estradiol. 14th World Congress of Gynecological Endocrinology, Florence, Italy, 2010.
104. Duijkers I, Klipping C, Grob P, Korver T. Effects of a unique, monophasic combined oral contraceptive containing nomegestrol acetate/17 beta-estradiol on ovarian function. 14th World Congress of Gynecological Endocrinology, Florence, Italy, 2010.
105. Gaussem P, Alhenc-Gelas M, Thomas JL, et al. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17 beta-estradiol, compared with those of levonorgestrel/ ethinyl estradiol. 14th World Congress of Gynecological Endocrinology, Florence, Italy, 2010.
106. Shrader SP, Dickerson LM. Extended- and continuous-cycle oral contraceptives. Pharmacotherapy 2008;28:1033-1040.
107. Edelman AB, Gallo MF, Jensen JT, et al. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database of Systematic Reviews (online) 2005:CD004695.
108. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: A meta-analysis. Circulation 2008;117:93-102. (Pubitemid 350301144)
109. Pomp ER, le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: Obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007;139:289-296. (Pubitemid 47493087)
110. Pomp ER, Rosendaal FR, Doggen CJ. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol 2008;83:97-102.
111. Shapiro S. Oral contraceptives, hormone therapy and cardiovascular risk. Climacteric 2008;11:355-363.
112. Allais G, Gabellari IC, Mana O, et al. Migraine and stroke: The role of oral contraceptives. Neurol Sci 2008;29 (Suppl 1):S12-14.
113. Allais G, Gabellari IC, De Lorenzo C, Mana O, Benedetto C. Oral contraceptives in migraine. Expert Rev Neurotherapeutics 2009;9:381-393.
114. Kaunitz AM. Clinical practice. Hormonal contraception in women of older reproductive age. N Engl J Med 2008;358:1262-1270. (Pubitemid 351439227)